Alliancebernstein L.P. Lowers Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Alliancebernstein L.P. reduced its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,578,393 shares of the life sciences company’s stock after selling 443,597 shares during the period. Alliancebernstein L.P. owned approximately 3.34% of Integra LifeSciences worth $58,478,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank purchased a new position in Integra LifeSciences during the fourth quarter worth about $8,967,000. Systematic Financial Management LP grew its holdings in shares of Integra LifeSciences by 53.9% during the third quarter. Systematic Financial Management LP now owns 611,746 shares of the life sciences company’s stock worth $11,115,000 after purchasing an additional 214,272 shares in the last quarter. Access Investment Management LLC purchased a new position in shares of Integra LifeSciences during the fourth quarter worth about $4,416,000. Charles Schwab Investment Management Inc. increased its position in shares of Integra LifeSciences by 15.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 944,282 shares of the life sciences company’s stock worth $17,158,000 after purchasing an additional 125,620 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Integra LifeSciences by 130.5% in the fourth quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company’s stock valued at $4,529,000 after purchasing an additional 113,061 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

IART opened at $19.57 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $34.79. The stock’s 50 day simple moving average is $23.37 and its 200 day simple moving average is $22.27. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -217.42, a PEG ratio of 0.73 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last issued its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 earnings per share. As a group, analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. Three analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $23.00.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.